How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Celiac Diseases Drugs Market
- By Drug Type: Enzyme Supplements, Immunomodulators, Anti-inflammatory Agents, Nutritional Supplements, Biologics
- By Route of Administration: Oral, Injectable, Topical
- By Mechanism of Action: Gluten Degradation, Immune Response Modulation, Intestinal Barrier Protection, Inflammation Reduction
- By Patient Type: Pediatric, Adult, Geriatric
- By Treatment Approach: Symptomatic Treatment, Disease-Modifying Treatment, Dietary Supplementation
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzyme Supplements leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Celiac Diseases Drugs Market report
A complete, evidence-based study - 12 chapters and 116 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Route of Administration 3
Mechanism of Action 4
Patient Type 3
Treatment Approach 3
Companies profiled
Alvine Pharmaceuticals
ImmusanT
Takeda Pharmaceutical Company
Nestlé Health Science
Innovate Biopharmaceuticals
Synergy Pharmaceuticals
Thermo Fisher Scientific
BiomX
Celimmune
Ironwood Pharmaceuticals
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Alvine Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →ImmusanT
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Takeda Pharmaceutical Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nestlé Health Science
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Innovate Biopharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Synergy Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →BiomX
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Celimmune
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Ironwood Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,744M by 2033 · 8.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzyme Supplements45.6
- Immunomodulators15.2
- Anti-inflammatory Agents20.6
- Nutritional Supplements7.2
- Biologics11.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$662.8M → $1,166M · 7.3%
Europe$462.0M → $804.5M · 7.2%
Asia Pacific$421.8M → $761.5M · 7.7%
Latin America$261.1M → $542.6M · 9.6%
Middle East and Africa$200.9M → $336.4M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.062026
8.052027
8.072028
8.092029
8.092030
8.112031
8.112032
8.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Alvine Pharmaceuticals19.1
- ImmusanT23.1
- Takeda Pharmaceutical Company11.4
- Nestlé Health Science3.7
- Innovate Biopharmaceuticals4.8
- Synergy Pharmaceuticals9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type14.3%
Route of Administration16.0%
Mechanism of Action23.0%
Patient Type22.8%
Treatment Approach23.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe22.3
- Asia Pacific21.1
- Latin America15.0
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Alvine Pharmaceuticals | 89 | 91 | 99 | 75 | 80 | 80 | 86 |
| ImmusanT | 75 | 83 | 90 | 70 | 88 | 69 | 79 |
| Takeda Pharmaceutical Company | 84 | 64 | 65 | 70 | 86 | 70 | 73 |
| Nestlé Health Science | 66 | 74 | 77 | 81 | 81 | 73 | 75 |
| Innovate Biopharmaceuticals | 60 | 58 | 68 | 61 | 71 | 72 | 65 |
| Synergy Pharmaceuticals | 66 | 66 | 47 | 53 | 63 | 64 | 60 |
| Thermo Fisher Scientific | 42 | 52 | 56 | 64 | 49 | 52 | 53 |
| BiomX | 60 | 42 | 38 | 46 | 49 | 56 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Alvine Pharmaceuticals
- ImmusanT
- Takeda Pharmaceutical Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Alvine Pharmaceuticals | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| ImmusanT | ◐ | ✓ | ◐ | − | ✓ | ◐ |
| Takeda Pharmaceutical Company | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Nestlé Health Science | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Innovate Biopharmaceuticals | − | − | ◐ | ◐ | − | ✓ |
| Synergy Pharmaceuticals | ◐ | ◐ | − | − | − | − |
| Thermo Fisher Scientific | − | − | − | ◐ | ◐ | ◐ |
| BiomX | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Alvine Pharmaceuticals86
2ImmusanT79
3Nestlé Health Science75
4Takeda Pharmaceutical Company73
5Innovate Biopharmaceuticals65
6Synergy Pharmaceuticals60
7Thermo Fisher Scientific53
8BiomX49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Alvine PharmaceuticalsImmusanT
Challenger2
Strong scale, closing on the leaders.
Takeda Pharmaceutical CompanyNestlé Health Science
Contender2
Focused players with pockets of strength.
Innovate BiopharmaceuticalsSynergy Pharmaceuticals
Niche2
Specialists in a single segment or region.
Thermo Fisher ScientificBiomX
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Celiac Diseases Drugs Market — a $274M beachhead inside a $4.22B market.
Beachhead (SOM)$274Mobtainable near-term
Serviceable (SAM)$1.77Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Enzyme Supplements
Best fit — highest urgency & budget in Drug Type.
Economic buyer75 fit
Immunomodulators
Strong fit — clear ROI and a fast path to value.
End user66 fit
Anti-inflammatory Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Celiac Diseases Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won8%
$12.6KCAC
$74KLTV
5.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Celiac Diseases Drugs Market is a durable-growth opportunity — $2.48B by 2033, compounding at 7.1%.
TAM · 2025$1.43Btoday
TAM · 2033$2.48Bforecast
CAGR7.1%2027–2033
Cumulative$17.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.48BTotal addressable market
SAM$1.02BServiceable available market
SOM$201MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.1% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.48BLarge & growingTAM by 2033 at 7.1% CAGR
$1.02BServiceable nowreachable with today’s model
$201MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.93BBear4.6% CAGR
$2.48BBase7.1% CAGR
$3.17BBull9.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Celiac Diseases Drugs Market — a $3.84B market by 2033. Plan: grow share from 8.8% to 17.6%.
Market size · 2033$3.84Btotal addressable
Market CAGR3.7%2027–2033
Target share17.6%from 8.8% today
Revenue ambition$676Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 17.6% | Behind |
| Revenue | $315M | $676M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.8% | 43.3% | At risk |
| Customer retention | 90.3% | 96.3% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $71M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Celiac Diseases Drugs Market conversation — a $5.48B market you can size, segment and defend in minutes.
Market size · 2033$5.48Btotal opportunity
Growth4.7%CAGR to 2033
Addressable buyers1,527+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 3 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Alvine PharmaceuticalsImmusanTTakeda Pharmaceutical CompanyNestlé Health ScienceInnovate BiopharmaceuticalsSynergy PharmaceuticalsThermo Fisher ScientificBiomX+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Celiac Diseases Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Celiac Diseases Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cell & Advanced Therapies Supply Chain Management Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCell & Gene Delivery Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCell & Gene Therapy Cold Chain Logistics Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCell & Gene Therapy Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCell Activation Devicer Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCell Analyzer Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCell and Gene Therapy (CGT) Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCell and Gene Therapy CDMO Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportCell and Gene Therapy CDMO Services Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCell and Gene Therapy Related Products Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCell Anemia Testing & Screening Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCell Assay Reagents Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.